Showing results (1291-1300 of 1,302) with videos related to

Sort By:
Pageof 131
Journal of Neuroinflammation|November 4, 2024
Flow cytometry identifies changes in peripheral and intrathecal lymphocyte patterns in CNS autoimmune disorders and primary CNS malignanciesSaskia Räuber, Andreas Schulte-Mecklenbeck, Alice Willison, et al.
Nature Communications|April 8, 2026
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trialFrank A Giordano, Julian P Layer, Roberta Turiello, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 17, 2023
Climate change, human health, and resilience in the HoloceneGwen Robbins Schug, Jane E Buikstra, Sharon N DeWitte, et al.
European Urology Open Science|July 11, 2022
The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk CalculatorSneha Parekh, Parita Ratnani, Ugo Falagario, et al.
Journal of Electrocardiology|July 19, 2023
Education curriculum assessment for teaching electrocardiography: Rationale and design for the prospective, international, randomized controlled EDUCATE trialAnthony H Kashou, Peter A Noseworthy, Thomas J Beckman, et al.
Journal of Medicinal Chemistry|May 7, 2010
The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonistsWayne E Childers, Lisa M Havran, Magda Asselin, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
Epilepsia|January 14, 2026
Quantifying the impact of a computer-aided diagnostic score on the clinical diagnosis of functional seizuresWesley T Kerr, Katherine N McFarlane, Corinne H Allas, et al.
JAMA Neurology|January 20, 2026
Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal LeukoencephalopathyNora Möhn, Lea Grote-Levi, Agnes Bonifacius, et al.
Journal of Medicinal Chemistry|December 21, 2021
Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of PainGregory L Adams, Parul S Pall, Steven M Grauer, et al.
Pageof 131